Endocyte, Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its technology to create small molecule drug conjugates (SMDCs), and companion imaging diagnostics. Its SMDCs target receptors that are over-expressed on diseased cells, primarily to healthy cells. The Company�s SMDCs consists of three modules: a targeting ligand, a linker and a drug payload. The foundation of its technology is its small molecule targeting ligands, which bind to over-expressed receptors on target cells, while avoiding healthy cells. It is developing a number of different targeting ligands for a range of cancers and inflammatory diseases. Its linker system attaches the targeting ligand to the drug payload. The drug payload is the biologically active component of its SMDCs. Endocyte�s core SMDC, EC145, targets the folate receptor.